Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Wedbush

Keros Therapeutics (NASDAQ:KROS) was downgraded by stock analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. They currently have a $15.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 38.76% from the company’s current price.

KROS has been the topic of several other reports. Scotiabank reduced their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. HC Wainwright lowered their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.56.

Keros Therapeutics Stock Performance

KROS traded up $0.29 on Friday, reaching $10.81. The company had a trading volume of 1,560,779 shares, compared to its average volume of 2,448,567. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The company has a market cap of $437.91 million, a price-to-earnings ratio of -2.07 and a beta of 1.43. The business has a 50 day simple moving average of $37.51 and a 200 day simple moving average of $47.36.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same period in the prior year, the company earned ($1.33) earnings per share. The business’s revenue was up 4750.0% compared to the same quarter last year. As a group, equities research analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently made changes to their positions in KROS. Geode Capital Management LLC raised its holdings in shares of Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after acquiring an additional 46,041 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the period. Barclays PLC raised its position in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after acquiring an additional 35,022 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Keros Therapeutics in the 3rd quarter valued at approximately $603,000. Finally, Point72 Asset Management L.P. boosted its position in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.